Twenty-five years without progress: The enduring challenge of soft tissue sarcomas

Area of Science:

• Oncology
• Cancer Research
• Epidemiology

Background:

• Recent advancements in oncology have significantly improved survival rates for many cancers, including breast and lung cancer.
• However, the progress for soft tissue sarcoma (STS) has lagged behind other malignancies.
• This analysis focuses on the survival trends of STS patients over a 20-year period.

Purpose of the Study:

• To evaluate the survival trends of patients with soft tissue sarcoma (STS) from 1999 to 2019.
• To compare the survival outcomes of STS with those of gastrointestinal stromal tumors (GIST) during the same period.
• To identify factors contributing to the stagnation in STS survival and contrast them with GIST progress.

Main Methods:

• Analysis of data from 21,948 patients with STS (excluding GIST) using the Surveillance, Epidemiology, and End Results 9 registries.
• Inclusion of 3,716 patients diagnosed with GIST for comparative analysis.
• Stratification of data by disease stage (localized or distant) and time intervals to assess survival trends.

Main Results:

• Median survival for STS remained stagnant between 1999 and 2019, with no significant difference observed across disease stages.
• In contrast, GIST patients experienced a steady improvement in median survival, increasing from 105 months (1999-2004) to 122 months (2005-2011).
• These GIST survival improvements were noted in both localized and distant disease settings.

Conclusions:

• The lack of progress in STS survival is attributed to poor understanding of biological mechanisms, research challenges in rare diseases, and limited commercial interest.
• The contrasting positive outcomes in GIST suggest that understanding biological drivers can lead to targeted therapies and improved survival.
• Further research into the biological underpinnings of STS is crucial for developing effective treatments and improving patient prognoses.